Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) have moved 44.19% so far this year and they are now 82.16% from where they were around this time last year.
Over the last six months the stock has moved 71.15%, while it has moved 48.03% over the last quarter. Over the last week and the last one month, the stock has moved 20.66% and 65.67%, respectively.
The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction. Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.
Recently, Akebia Therapeutics, Inc. (NASDAQ:AKBA) announced that the company granted three newly hired employees options to purchase an aggregate of 9,000 shares of Akebia’s common stock with a per share exercise price of $13.18, the closing price on the grant date. These options will vest as to 25% of the total number of shares subject to the option on the first anniversary of the grant date. The remaining 75% of shares will vest ratably on the first day of each calendar quarter over the next three years. The stock options were inducements material to these new employees entering into employment with the company, and issued in reliance on NASDAQ Listing Rule 5635(c)(4).
Studying the stock?s moving averages shows its 20-Day Simple Moving Average to be $28.95% while 50-Day Simple Moving Average is $47.68% and 200-Day Simple Moving Average is $61.90%.
The stock has declined to a low of $74.94% over the last 50 days and jumped to a high of $7.68% over the same period. However, the stock?s price range over the last 12 months is a high of $7.68% and a low of $114.43%.
Analysts tracking Akebia Therapeutics, Inc. have an average recommendation of 2.00 on its stock. For clarity, recommendation of 1 implies STRONG BUY, 3 implies HOLD and 5 implies SELL.
The stock is currently trading at $15.01, but it should be trading at $20.00 by the end of the next 12 months according to analysts.
The stock’s average volume, which is the average of three months, is 839.82K, while its relative volume is 9.07.
Insiders own 1.80% of Akebia Therapeutics, Inc., while institutional investors own 57.90% of the company.
Of the company’s 37.24M shares outstanding, 31.82M are free float. Of the floating shares, 5.68% have been sold short and that brings short ratio to 2.15.
Akebia Therapeutics, Inc. reported EPS for the last fiscal year and the current year’s EPS is expected to increase -56.90% over the previous year’s EPS.